HTG Molecular Diagnostics Inc.07.19.17
HTG Molecular Diagnostics Inc., a provider of instruments, reagents and services for molecular profiling applications, has launched its new HTG EdgeSeq PATH Assay for sale in the United States and Europe.
The HTG EdgeSeq PATH Assay has been designed for retrospective gene expression profiling (GEP) to complement traditional immunohistochemistry (IHC) testing by allowing investigators to assess mRNA expression of large numbers of biomarkers when formalin-fixed, paraffin-embedded (FFPE) sample availability is limited. The assay is designed to detect up to 470 mRNA targets, typically assessed by IHC.
“We believe the trend toward smaller and less invasive biopsy methods, from which more and more information is needed, drives the market for our new HTG EdgeSeq PATH Assay,” stated T.J. Johnson, president and CEO of HTG. “We expect this product to enable simple and cost effective retrospective studies, which, ultimately, could lead to new GEP-based diagnostic, prognostic and predictive classifiers in solid tumors and clinical IHC-replacement products, and an estimated $1.5 billion market opportunity.”
“We designed this assay to enable our customers to profile small tissue biopsies in a more comprehensive manner than conventional IHC permits, and we expect this additional GEP information to advance research that, in the end, will improve patient care,” stated Patrick Roche, Ph.D., HTG’s senior vice president of Research & Development.
Headquartered in Tucson, Ariz., the mission of HTG Molecular Diagnostics (HTG) is to empower precision medicine at the local level. In 2013 the company commercialized its first instrument platform and a portfolio of RNA assays that leveraged HTG's original proprietary nuclease protection chemistry. Continuous improvement led to the 2014 launch of the company’s HTG EdgeSeq product line, which automates sample and targeted library preparation for next-generation sequencing.
The HTG EdgeSeq PATH Assay has been designed for retrospective gene expression profiling (GEP) to complement traditional immunohistochemistry (IHC) testing by allowing investigators to assess mRNA expression of large numbers of biomarkers when formalin-fixed, paraffin-embedded (FFPE) sample availability is limited. The assay is designed to detect up to 470 mRNA targets, typically assessed by IHC.
“We believe the trend toward smaller and less invasive biopsy methods, from which more and more information is needed, drives the market for our new HTG EdgeSeq PATH Assay,” stated T.J. Johnson, president and CEO of HTG. “We expect this product to enable simple and cost effective retrospective studies, which, ultimately, could lead to new GEP-based diagnostic, prognostic and predictive classifiers in solid tumors and clinical IHC-replacement products, and an estimated $1.5 billion market opportunity.”
“We designed this assay to enable our customers to profile small tissue biopsies in a more comprehensive manner than conventional IHC permits, and we expect this additional GEP information to advance research that, in the end, will improve patient care,” stated Patrick Roche, Ph.D., HTG’s senior vice president of Research & Development.
Headquartered in Tucson, Ariz., the mission of HTG Molecular Diagnostics (HTG) is to empower precision medicine at the local level. In 2013 the company commercialized its first instrument platform and a portfolio of RNA assays that leveraged HTG's original proprietary nuclease protection chemistry. Continuous improvement led to the 2014 launch of the company’s HTG EdgeSeq product line, which automates sample and targeted library preparation for next-generation sequencing.